Skip to content

Veterans Intensive Personalized Treatment in Heart Failure

VIP (Veterans Intensive Personalized) Treatment in Heart Failure

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01404988
Acronym
VIP
Enrollment
99
Registered
2011-07-28
Start date
2011-11-30
Completion date
2014-06-30
Last updated
2015-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Keywords

Heart Failure, Telemedicine, Medication Adherence

Brief summary

In the VIP (Veterans Intensive Personalized) Treatment in Heart Failure Study we will assess 2 novel interventions to enhance adherence and improve quality of life in veterans with heart failure. This 3-arm randomized controlled trial will base one active arm on how ready patients are for change in terms of diet and medication adherence and will tailor the intervention based on this. The other active arm will also assess how ready patients are for change, but will also include tailoring based on availability of environment resources, such as proximity to health food stores or social support, to further tailor the intervention. The last active arm is simply an attention group where patients will receive general health counseling in addition to background care that all patients receive. The overarching hypothesis is that the tailored interventions will lower heart failure (HF) recurrence and improve quality of life by better medication and diet adherence compared to attention placebo.

Detailed description

OBJECTIVES: In the VIP (Veterans Intensive Personalized) Treatment in Heart Failure Study we will assess 2 novel interventions to enhance adherence and improve quality of life (QOL) in veterans with heart failure (HF). This theory-based pilot 3-arm randomized controlled trial (RCT) will base one active arm on the Transtheoretical Model (TTM), while the other active arm will add environmental (built and human) tailoring to TTM. The overarching hypothesis driving this proposal is that a behavioral intervention (BI), which uses the TTM, or a behavioral and environment-tailored intervention (BEI) will lower HF recurrence and improve QOL by better medication and diet adherence compared to attention control. RESEARCH DESIGN: This is a practice-based RCT to test the effect of BI and BEI on medication and diet adherence. The study is embedded in typical VA healthcare with all 3 arms incorporating the enhancements in HF care that have been implemented including the Patient Aligned Care Teams (PACT), system redesign methods to improve HF care, ongoing HF quality improvement and Telehealth. We will randomize 99 participants equally to BI, BEI and AP. All analyses will be intent to treat. METHODOLOGY: The study sites will be the VAMC's at Manhattan and Brooklyn. Participants will be veterans with classes I-III HF with prescribed HF medication for 6 months. Men and women ( 21 years) with history and clinical findings of chronic, stable HF of NYHA functional class I (previously symptomatic/now asymptomatic), II, or III are eligible. They must have an available phone and 2 clinic visits in the previous 1.5 years. Patients with poor short-term survival (\< 1 year), recent major surgery (\< 3 months), temporarily in the area, or those unable to provide consent will be excluded. After being screened for eligibility, participants will come in for 2 study visits over the course of 6 months which will last about 1.5-2 hours. At each visit, a research assistant (RA) will administer a questionnaire assessing health behaviors including diet, exercise and medication and quality of life. The RAs will also measure height, weight, take 6 BP readings, and send patients to the lab for blood and urine samples. After the first clinic visit, participants will be randomized to one of three telephone groups. All participants will receive 1 phone call per month for 6 months which will last approximately 30-40 minutes. 1) The BI group will receive TTM stage-matched counseling. The interventionist will assess how ready patients are for change in terms of diet, medication, and exercise adherence and deliver a tailored intervention discussing adherence barriers. 2) In the BEI, in addition to using the TTM, the intervention will tailor environmental factors, such as availability of healthy food stores, recreational facilities, and support from caregivers in helping participants follow treatment recommendations. We will speak with participant's caregivers to educate them on heart failure as well. The caregivers will receive a call every 2 months (3 in total) lasting approximately 20-30 minutes. 3) The control group will receive monthly telephone calls during which they will receive general health education. Our primary analytic goal is to estimate the medication adherence rate and QOL to power a larger study. We will also perform 1-sample Exact Binomial Tests comparing the active arms to the expected inactive control rate of 47%. Since this is a pilot study, we will use a 5% type 1 error rate (2-sided) for each test. All analyses will be intent to treat.

Interventions

BEHAVIORALTelephone-Delivered BI

Behavioral Intervention will be delivered over the phone.

BEHAVIORALTelephone-Delivered BEI

Behavioral and Environmental Intervention will be delivered over the phone

OTHERTelephone-Delivered API

Attention Placebo Intervention will be delivered over the phone

Sponsors

US Department of Veterans Affairs
Lead SponsorFED

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Men and women (21 years) with history and clinical findings of chronic, stable HF of NYHA functional class I (previously symptomatic/now asymptomatic), II, or III. * They must have an available phone and 2 clinic visits in the previous 1.5 years.

Exclusion criteria

* Patients with poor short-term survival (\< 1 year) * recent major surgery (\< 3 months) * temporarily in the area * or those unable to provide consent will be excluded. * Patients excluded and reason for exclusion will be recorded.

Design outcomes

Primary

MeasureTime frameDescription
Medication Adherence (Refill Compliance for All HF Medications)6 months from baseline visitRefill compliance is an objective measurement of medication adherence that utilizes pharmacy records to assess the proportion of time a patient has medication available to take. At the original release of the medication, and each subsequent refill, individuals are given enough medication to last a set number of days. This number is referred to as the Days Supply and can be calculated by dividing the number of pills prescribed by the number of pills taken per day. To calculate compliance, the Days Supply is subtracted by the number of days between Actual Refill dates, a time span referred to as the Days Passed. If the Days Passed exceeds the Days Supply the absolute value of the difference represents the number of days the individual was non-adherent. This absolute value is referred to as a Gap. The sum of the Gaps/total number of days passed between the original release of the medication and the final recorded refill date represents non-compliance over that period of time.

Secondary

MeasureTime frameDescription
Adherence to ACE Inhibitors and ARB6 months after baselineRefill compliance is an objective measurement of medication adherence that utilizes pharmacy records to assess the proportion of time a patient has medication available to take. At the original release of the medication, and each subsequent refill, individuals are given enough medication to last a set number of days. This number is referred to as the Days Supply and can be calculated by dividing the number of pills prescribed by the number of pills taken per day. To calculate compliance, the Days Supply is subtracted by the number of days between Actual Refill dates, a time span referred to as the Days Passed. If the Days Passed exceeds the Days Supply the absolute value of the difference represents the number of days the individual was non-adherent. This absolute value is referred to as a Gap. The sum of the Gaps/total number of days passed between the original release of the medication and the final recorded refill date represents non-compliance over that period of time.
Adherence to Beta Blockers6 months from baselineRefill compliance is an objective measurement of medication adherence that utilizes pharmacy records to assess the proportion of time a patient has medication available to take. At the original release of the medication, and each subsequent refill, individuals are given enough medication to last a set number of days. This number is referred to as the Days Supply and can be calculated by dividing the number of pills prescribed by the number of pills taken per day. To calculate compliance, the Days Supply is subtracted by the number of days between Actual Refill dates, a time span referred to as the Days Passed. If the Days Passed exceeds the Days Supply the absolute value of the difference represents the number of days the individual was non-adherent. This absolute value is referred to as a Gap. The sum of the Gaps/total number of days passed between the original release of the medication and the final recorded refill date represents non-compliance over that period of time.
Self-reported Medication Adherence6 months from baselineAssessed using Morisky medication-taking scale. Higher score corresponds to worse adherence.

Countries

United States

Participant flow

Participants by arm

ArmCount
Comprehensive Behavioral Intervention (BI)
Participants will receive the BI that is based on the transtheoretical model, which targets stage of change, decisional balance and self-efficacy, while also assessing and counseling regarding the barriers and facilitators of HF care, and to improve self-regulatory care such as self-monitoring, self-evaluation, feedback and reinforcement.Behavioral Intervention will be delivered over the phone.
33
Behavioral and Environmental Intervention (BEI)
Participants in this arm will receive the BI but will also receive environmental tailoring. Environmental Tailoring consists of Built Environment Tailoring (BET) where the intervention will incorporate aspects from the patients' environment, such as accessibility of health food stores or recreational facilities. Environmental Tailoring also consists of Human Environment Tailoring (HET) which incorporates patients' social support. Caregivers will be enrolled for patients in this arm of the study and they will also receive health education. Behavioral and Environmental Intervention will be delivered over the phone
33
Attention Placebo Intervention (API)
Patients will receive non-tailored counseling on general health topics. Attention Placebo Intervention will be delivered over the phone
33
Total99

Withdrawals & dropouts

PeriodReasonFG000FG001FG002
Overall StudyAdverse Event100
Overall StudyDeath202
Overall StudyLost to Follow-up121
Overall StudyWithdrawal by Subject220

Baseline characteristics

CharacteristicTotalComprehensive Behavioral Intervention (BI)Behavioral and Environmental Intervention (BEI)Attention Placebo Intervention (API)
Age, Continuous67.0 years65.9 years67.7 years67.6 years
Campus
Brooklyn
60 participants19 participants21 participants20 participants
Campus
Manhattan
39 participants14 participants12 participants13 participants
Education
High School Graduate or Below
9 participants3 participants4 participants2 participants
Education
Some College or Higher
90 participants30 participants29 participants31 participants
Employment Status
Employed
12 participants2 participants5 participants5 participants
Employment Status
Not Employed
87 participants31 participants28 participants28 participants
Ischemic Heart Disease (IHD)
History of IHD
2 participants0 participants1 participants1 participants
Ischemic Heart Disease (IHD)
No History of IHD
97 participants33 participants32 participants32 participants
Marital Status
Married
66 participants25 participants16 participants25 participants
Marital Status
Not Married
33 participants8 participants17 participants8 participants
Medication Adherence
High Adherence
36 participants13 participants9 participants14 participants
Medication Adherence
Low adherence
18 participants5 participants9 participants4 participants
Medication Adherence
Medium Adherence
45 participants15 participants15 participants15 participants
Number of Heart Failure Medications3.0 number of heart failure medications3.0 number of heart failure medications3.0 number of heart failure medications3.0 number of heart failure medications
Prescribed ACE inhibitors or Angiotensin II Receptor Blockers (ABRs)
Not prescribed ACE and/or ARB
20 participants10 participants8 participants2 participants
Prescribed ACE inhibitors or Angiotensin II Receptor Blockers (ABRs)
Prescribed ACE and/or ARB
79 participants23 participants25 participants31 participants
Prescribed Beta Blockers
Not prescribed Beta Blockers
8 participants1 participants2 participants5 participants
Prescribed Beta Blockers
Prescribed Beta Blockers
91 participants32 participants31 participants28 participants
Race/Ethnicity, Customized
Black (Non-Hispanic)
36 participants13 participants9 participants14 participants
Race/Ethnicity, Customized
Hispanic
13 participants4 participants8 participants1 participants
Race/Ethnicity, Customized
Other
6 participants2 participants2 participants2 participants
Race/Ethnicity, Customized
White (Non-Hispanic)
44 participants14 participants14 participants16 participants
Sex: Female, Male
Female
1 Participants1 Participants0 Participants0 Participants
Sex: Female, Male
Male
98 Participants32 Participants33 Participants33 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
— / —— / —— / —
other
Total, other adverse events
4 / 330 / 333 / 33
serious
Total, serious adverse events
6 / 331 / 333 / 33

Outcome results

Primary

Medication Adherence (Refill Compliance for All HF Medications)

Refill compliance is an objective measurement of medication adherence that utilizes pharmacy records to assess the proportion of time a patient has medication available to take. At the original release of the medication, and each subsequent refill, individuals are given enough medication to last a set number of days. This number is referred to as the Days Supply and can be calculated by dividing the number of pills prescribed by the number of pills taken per day. To calculate compliance, the Days Supply is subtracted by the number of days between Actual Refill dates, a time span referred to as the Days Passed. If the Days Passed exceeds the Days Supply the absolute value of the difference represents the number of days the individual was non-adherent. This absolute value is referred to as a Gap. The sum of the Gaps/total number of days passed between the original release of the medication and the final recorded refill date represents non-compliance over that period of time.

Time frame: 6 months from baseline visit

ArmMeasureValue (MEDIAN)
Comprehensive Behavioral Intervention (BI) -Medication Adherence (Refill Compliance for All HF Medications)0.94 proportion of refill compliance
Behavioral & Environmental Intervention (BEI)Medication Adherence (Refill Compliance for All HF Medications)0.97 proportion of refill compliance
Attention Placebo Group (API)Medication Adherence (Refill Compliance for All HF Medications)0.99 proportion of refill compliance
p-value: 0.1Wilcoxon (Mann-Whitney)
p-value: 0.2Wilcoxon (Mann-Whitney)
Secondary

Adherence to ACE Inhibitors and ARB

Refill compliance is an objective measurement of medication adherence that utilizes pharmacy records to assess the proportion of time a patient has medication available to take. At the original release of the medication, and each subsequent refill, individuals are given enough medication to last a set number of days. This number is referred to as the Days Supply and can be calculated by dividing the number of pills prescribed by the number of pills taken per day. To calculate compliance, the Days Supply is subtracted by the number of days between Actual Refill dates, a time span referred to as the Days Passed. If the Days Passed exceeds the Days Supply the absolute value of the difference represents the number of days the individual was non-adherent. This absolute value is referred to as a Gap. The sum of the Gaps/total number of days passed between the original release of the medication and the final recorded refill date represents non-compliance over that period of time.

Time frame: 6 months after baseline

ArmMeasureValue (MEDIAN)
Comprehensive Behavioral Intervention (BI) -Adherence to ACE Inhibitors and ARB0.98 proportion of refill compliance
Behavioral & Environmental Intervention (BEI)Adherence to ACE Inhibitors and ARB1.0 proportion of refill compliance
Attention Placebo Group (API)Adherence to ACE Inhibitors and ARB1.0 proportion of refill compliance
p-value: 0.3Wilcoxon (Mann-Whitney)
p-value: 0.77Wilcoxon (Mann-Whitney)
Secondary

Adherence to Beta Blockers

Refill compliance is an objective measurement of medication adherence that utilizes pharmacy records to assess the proportion of time a patient has medication available to take. At the original release of the medication, and each subsequent refill, individuals are given enough medication to last a set number of days. This number is referred to as the Days Supply and can be calculated by dividing the number of pills prescribed by the number of pills taken per day. To calculate compliance, the Days Supply is subtracted by the number of days between Actual Refill dates, a time span referred to as the Days Passed. If the Days Passed exceeds the Days Supply the absolute value of the difference represents the number of days the individual was non-adherent. This absolute value is referred to as a Gap. The sum of the Gaps/total number of days passed between the original release of the medication and the final recorded refill date represents non-compliance over that period of time.

Time frame: 6 months from baseline

ArmMeasureValue (MEDIAN)
Comprehensive Behavioral Intervention (BI) -Adherence to Beta Blockers0.95 proportion of refill compliance
Behavioral & Environmental Intervention (BEI)Adherence to Beta Blockers0.97 proportion of refill compliance
Attention Placebo Group (API)Adherence to Beta Blockers1.0 proportion of refill compliance
p-value: 0.03Wilcoxon (Mann-Whitney)
p-value: 0.06Wilcoxon (Mann-Whitney)
Secondary

Self-reported Medication Adherence

Assessed using Morisky medication-taking scale. Higher score corresponds to worse adherence.

Time frame: 6 months from baseline

ArmMeasureGroupValue (NUMBER)
Comprehensive Behavioral Intervention (BI) -Self-reported Medication AdherenceMedium adherence9 participants
Comprehensive Behavioral Intervention (BI) -Self-reported Medication AdherenceLow adherence2 participants
Comprehensive Behavioral Intervention (BI) -Self-reported Medication AdherenceHigh adherence16 participants
Behavioral & Environmental Intervention (BEI)Self-reported Medication AdherenceMedium adherence11 participants
Behavioral & Environmental Intervention (BEI)Self-reported Medication AdherenceLow adherence4 participants
Behavioral & Environmental Intervention (BEI)Self-reported Medication AdherenceHigh adherence14 participants
Attention Placebo Group (API)Self-reported Medication AdherenceLow adherence1 participants
Attention Placebo Group (API)Self-reported Medication AdherenceHigh adherence21 participants
Attention Placebo Group (API)Self-reported Medication AdherenceMedium adherence8 participants
p-value: 0.6Fisher Exact
p-value: 0.16Fisher Exact

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026